W
Wouter F W Bierman
Researcher at University Medical Center Groningen
Publications - 49
Citations - 1180
Wouter F W Bierman is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Ritonavir & Outpatient clinic. The author has an hindex of 14, co-authored 44 publications receiving 936 citations. Previous affiliations of Wouter F W Bierman include VU University Medical Center & VU University Amsterdam.
Papers
More filters
Journal ArticleDOI
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Wouter F W Bierman,Michiel A. van Agtmael,Monique Nijhuis,S. A. Danner,Charles A. Boucher,Charles A. Boucher +5 more
TL;DR: The overall efficacy of ritonavir-boosted protease inhibitor monotherapy is inferior to HAART, but the efficacy improves in patients started on monotherapy after suppressed HIV-RNA for at least 6 months, and a broader use of simplification of HAART to protease inhibitors monotherapy might be justified.
Journal ArticleDOI
Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy
Anne Boerekamps,Guido E.L. van den Berk,F. N. Lauw,Eliane M. S. Leyten,Marjo E. E. van Kasteren,Arne van Eeden,Dirk Posthouwer,Mark A. A. Claassen,Anton S M Dofferhoff,D. W. M. Verhagen,Wouter F W Bierman,Kamilla D. Lettinga,Frank P. Kroon,Corine E Delsing,Paul H. P. Groeneveld,Robert Soetekouw,Edgar J G Peters,Sebastiaan J. Hullegie,Stephanie Popping,David A. M. C. van de Vijver,Charles A. Boucher,Joop E. Arends,Bart J. A. Rijnders +22 more
TL;DR: Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute HCV infections among HIV-positive MSM, which contradicts a decrease in risk behavior as an alternative explanation.
Journal ArticleDOI
Presentation and Diagnosis of Imported Schistosomiasis: Relevance of Eosinophilia, Microscopy for Ova, and Serology
TL;DR: Screening by serology is easy and reliable and the method of choice in asymptomatic persons with a history of freshwater exposure in a high-risk area and positive serology for schistosomal antibodies.
Journal ArticleDOI
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
Ingeborg E A Wijting,Casper Rokx,Charles A. Boucher,Jeroen J. A. van Kampen,Suzan D. Pas,Theodora E. M. S. de Vries-Sluijs,Carolina A. M. Schurink,Hannelore I. Bax,Maarten Derksen,Eleni-Rosalina Andrinopoulou,Marchina E. van der Ende,Eric C. M. van Gorp,Jan L. Nouwen,Annelies Verbon,Wouter F W Bierman,Bart J. A. Rijnders +15 more
TL;DR: Dolutegravir monotherapy was non-inferior to combination ART at 24 weeks, however, virological failure continued to occur thereafter and led to doluteg Gravir resistance, and the drug should not be used as maintenance monotherapy.
Journal ArticleDOI
Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium
Annemarie Rosan Kreeftmeijer-Vegter,Perry J.J. van Genderen,Leo G. Visser,Wouter F W Bierman,Jan Clerinx,Cees K. W. van Veldhuizen,Peter J. de Vries +6 more
TL;DR: Data from the named patient programme demonstrate that IV artesunate is effective and well-tolerated in European travellers lacking immunity, however, increased attention needs to be paid to the possible development of haemolytic anaemia 2-3 weeks after start of treatment.